Daniel L. Berta, left, Fairfield County Bank president, with Paul S. McNamara, chairman, and David A. Schneider, CEO.
Fairfield County Bank executives reported confidence in the bank’s strategies and future at the bank’s 143rd annual meeting on July 15 in Ridgefield.
Attendees included members of the Board of Directors, the Board of Incorporators and senior management of the bank. The Board of Incorporators represents business professionals from throughout Fairfield County. This year Andrew Montanari, president of Montanari Fuel Service, Inc., in Ridgefield, was elected to the Board of Incorporators. The annual meeting provides a forum for reporting to the incorporators of the bank about the financial well-being and the strategic initiatives of the bank.
Paul S. McNamara, chairman, David A. Schneider, CEO, and Daniel L. Berta, president, presented an overview of the banking industry, the impact of the existing economic environment, financial reports and the accomplishments of the bank. The presentations showed the organization has planned for economic conditions and is performing better than the peer group it uses in its benchmark and performance metrics, the bank said. Presenters were confident the bank will continue its strategic path and perform well in the coming year.
Presentation topics included enhancements in electronic banking, including the recently added mobile deposit, and community support with more than $800,000 in financial contributions and support to civic and non-profit organizations. Also noted was the decision to undertake a core processor enhancement, planned for second quarter 2015.
Headquartered in Ridgefield, Fairfield County Bank operates 18 branch offices throughout the county.
Boehringer druggets FDA OK
The U.S. Food and Drug Administration has approved a Boehringer Ingelheim drug for use by chronic obstructive pulmonary disease patients. The Ridgefield-based pharmaceutical firm reported the FDA approval on Aug. 1.
The new drug, Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg, is a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysemam, the firm reported.
The drug doesn’t treat “acute deteriorations of COPD and is not indicated to treat asthma,” according to the firm, and it comes with several safety warnings, including the risk of asthma-related death.